Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Moderna Falls After Reportedly Delaying Covid-19 Vaccine Trial

Published 07/02/2020, 01:10 PM
Updated 07/02/2020, 01:18 PM
© Reuters.
By Yasin Ebrahim
 
Investing.com - Moderna fell sharply Friday, as the drugmaker is reportedly delaying a clinical trial for its Covid-19 vaccine candidate. 
 
Moderna (NASDAQ:MRNA) fell 5%.
 
In a blow to the company's expectations to roll out key data from its coronavirus vaccine by Thanksgiving, Moderna's 30,000-patient trial of its coronavirus vaccine candidate, expected to start next week, has been delayed following changes to the protocol, Statnews reported.
 
The trial could still get underway in July as the company looks "close to being on target," Statnews said, citing one investigator.
 
“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator said. “As best I can tell, they’re close to being on target for that.”
 

 

Latest comments

Moderna is a great company, and it will deliver the vaccine as promised. ..sooner than expected.
Friday?...man this article is for tomorrow..today is Thursday
Man...like time haz his own zones...maaaan...like..me, but buying good sgtocks..duuuude! 😀👍🙃😎🤟👀🌱⬆️🤤
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.